Dr Steve Arlington

Objective considerations when gauging investment.

AI has become ubiquitous in all industries, including life sciences. But is also attracting some concerns – particularly around job losses, ethics, and more broadly, how successful it really is, writes Steve Arlington.

While pricing issues need to be addressed in a transparent manner, what cannot be disputed is that the vast majority of the industry is committed to the discovery of vital new medicines with the power to change patients’ lives, writes Dr Steve Arlington.